Some parts of healthcare depend on blockbuster products. This is not one of them.
Diagnostics and testing are more about repetition, throughput, and the simple fact that doctors still need answers before they do things.
That makes the space useful when you want healthcare exposure with a little less drama and a lot more recurring demand.
Stay Informed (Sponsored)
Recent reports have raised concerns about how assets are held in brokerage and retirement accounts.
In times of financial stress, ownership structures may not be as straightforward as they seem.
That’s why some investors are exploring alternative ways to diversify and protect their savings.
Get the free 2026 Gold Guide now
Theme: Diagnostics and Lab Testing: Recurring Answers for a Busy Healthcare System
This theme works because testing does not need a heroic consumer. It needs doctors, hospitals, patients, and health systems that are still moving.
When that happens, lab volume, diagnostic tools, and imaging agents can keep generating steady demand.
What’s Driving It
The latest numbers are supportive.
Labcorp reported 2025 revenue growth of more than 7%, double-digit adjusted EPS growth, margin expansion, and strong free cash flow, while saying Diagnostics and Central Laboratories were major drivers.
Danaher reported full-year 2025 revenue up 3% to $24.6 billion and guided to 2026 core revenue growth of 3% to 6%. Lantheus reported full-year 2025 revenue of $1.54 billion and bought back $100 million of stock in Q4.
Revvity ended 2025 with about $2.9 billion of revenue. Quest has not reported Q1 2026 yet, but it already set April 21 as its release date, which keeps the group in focus.
Here is the chain reaction:
Care demand stays active → testing demand stays active
Testing demand stays active → lab and diagnostic volume remains durable
Durable volume → operating leverage and mix help margins
Better margins → cash flow gets cleaner
Cleaner cash flow → buybacks, dividends, and reinvestment become easier to support
The Bulls Say
The easy bull case is that healthcare keeps moving even if the rest of the economy feels uncertain. Labs still process tests. Hospitals still need diagnostics.
Providers still rely on tools that reduce uncertainty and improve treatment decisions. If volumes stay stable and pricing does not get worse, this group can keep compounding.
The nice part is that each name gives you a different angle. Quest and Labcorp are the volume-and-scale plays. Danaher is the picks-and-shovels platform with better diversification.
Revvity gives you diagnostics tools and life-science leverage. Lantheus is the imaging specialist with more upside torque if product momentum stays strong.
The Bears Say
Lab volumes can still get noisy. Pricing pressure is always in the background. Policy, reimbursement, and payer mix can complicate what would otherwise be a very tidy story.
And some of these names, especially the more specialized ones, can be more product-dependent than they first appear.
Quest Diagnostics (DGX)
What it does: Large clinical laboratory and diagnostic testing provider.
Why it fits: Quest is the straightforward volume play. It has not yet reported Q1 2026, but it already scheduled the release for April 21, which keeps it squarely in the near-term setup.
Quest’s latest investor materials also show the business still leaning on recurring lab-test demand rather than one-off excitement.
The Pros:
Core testing volumes stay steady
Operating leverage improves as throughput remains healthy
The company reports a clean quarter and reminds investors why labs are durable
The stock benefits if healthcare defensiveness stays in favor
What to watch next: April 21 results, especially volume trends, margins, and management’s tone on demand.
Risk: If the quarter looks only okay in a market expecting sturdiness, the reaction can still be harsher than it deserves.
Labcorp (LH)
What it does: Diagnostics and laboratory services, plus central laboratory and related healthcare testing operations.
Why it fits: Labcorp looks like one of the cleaner operators in the group right now.
It said 2025 revenue grew more than 7%, adjusted EPS grew at a double-digit rate, margins expanded, and free cash flow stayed strong.
Management also said Diagnostics and Central Laboratories were key drivers and that 2026 began with strong momentum.
The Pros:
Diagnostics demand remains stable
Margin expansion continues
Cash flow stays strong enough to support capital returns
The stock gets more credit for execution quality
What to watch next: Q1 2026 results on April 30, especially diagnostics volume, margin follow-through, and guidance tone.
Risk: If volumes soften or reimbursement pressure creeps in, the market can cool on the story quickly.
Crude Surge (Sponsored)
Oil prices are on the rise, putting the energy sector back in the spotlight.
Large banks have raised their crude outlooks, and investors are reexamining which companies could benefit most if supply risks persist.
In a new report, Zacks highlights three oil stocks standing out in the current market backdrop.
Danaher (DHR)
What it does: Life sciences, diagnostics, and research tools platform.
Why it fits: Danaher is the broadest, cleanest platform in the basket.
It reported full-year 2025 revenue up 3% to $24.6 billion, adjusted EPS up 4.5% to $7.80, and guided to 2026 core revenue growth of 3% to 6%.
It also produced $6.4 billion of operating cash flow.
The Pros:
Diagnostics and life-science demand remain resilient
Margin and cash-flow quality keep supporting the premium
2026 guidance proves reachable or conservative
The market rewards the platform model in a choppier tape
What to watch next: Core growth by segment and whether management keeps sounding confident about 2026 without getting too promotional.
Risk: Premium-quality names still get hit if growth underwhelms.
Revvity (RVTY)
What it does: Diagnostics and life-science tools across testing, discovery, and lab workflows.
Why it fits: Revvity gives you a more specialized diagnostics-tools angle.
The company ended 2025 with about $2.9 billion of revenue and keeps showing up in diagnostics, lab, biotech, and government workflows, which gives the story multiple demand channels.
The Pros:
Testing and life-science demand remain healthy enough to support a cleaner multiple
The company keeps expanding in the right end markets
Revenue quality improves as execution stays consistent
Investors start rewarding it more like a durable diagnostics name than a leftover life-science tool story
What to watch next: Segment mix and whether management continues showing balanced demand rather than isolated strength in one niche.
Risk: Less obvious simplicity than Quest or Labcorp, which can make the story harder for investors to hold onto when the tape gets messy.
Tech Clash (Sponsored)
Donald Trump never forgets an insult.
And according to this Mar-a-Lago regular, he believes Trump's about to take his revenge on Elon Musk.
How? By releasing a radical new AI model more than 1,000X more powerful than Elon's Grok… just in time to leapfrog Elon's SpaceX IPO.
What's Trump up to? And how could it send shares of one AI stock (not SpaceX) soaring?
Click here for the full story.
This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.
Lantheus (LNTH)
What it does: Diagnostic imaging and radiopharmaceutical-focused healthcare company.
Why it fits: Lantheus adds some spice to an otherwise steadier group.
Full-year 2025 revenue reached $1.54 billion, adjusted EPS was $6.08, and the company repurchased $100 million of stock in Q4.
It also had a busy March with product and regulatory updates, which keeps it very much in play.
The Pros:
Imaging and radiodiagnostic demand stay strong
New approvals and pipeline progress expand the story
Share repurchases support investor confidence
The stock benefits if healthcare investors want more upside than the lab giants offer
What to watch next: Product momentum, pipeline timing, and whether recent regulatory developments support a better 2026 setup.
Risk: More product-specific risk than the broad lab names.
Want to make sure you never miss a stock recommendation?
Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell. Email’s great. Texts are faster.
This theme is useful because it sits in the middle of healthcare’s workflow. Testing still happens. Labs still process samples. Doctors still need better information before they make decisions.
That recurring demand gives this group a steadier foundation than many parts of healthcare. Watch volume, mix, and margin stability.
If those stay healthy, diagnostics and lab testing can keep doing what they do best: making money by helping the rest of the system figure things out.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
